Skip to content

Nateglinide

    Brands

    DEA Class; Rx

    Common Brand Names; Starlix

    • Antidiabetics, Meglitinides Derivatives

    Meglitinide oral hypoglycemic agent; stimulates insulin secretion
    Rapid onset and short duration of action replicates physiological insulin profiles around meals
    Used prior to meals for the treatment of type 2 diabetes mellitus in adults; not commonly used as monotherapy

    Indicated for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise.

    Not for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis

    Documented hypersensitivity

    Increased uric acid (10%)

    Dizziness (4%)

    Arthropathy (3%)

    Flu-like syndrome

    Weight gain

    Hypoglycemia (2%)

    Diarrhea

    Nausea

    Not to be used in combination with an insulin secretagogue (eg, glyburide)

    Not to be used as substitute for metformin monotherapy but as adjunctive

    There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with therapy

    Available data from published literature and applicant’s pharmacovigilance in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes

    There are no data on presence of nateglinide in human milk, effects on breastfeeding infant, or on milk production

    Adults

    360 mg/day PO.

    Elderly

    360 mg/day PO.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Nateglinide

    tablet

    • 60mg
    • 120mg